SPMS

January 8, 2018January 8, 2018

Trial of AB Science’s Progressive MS Therapy to Continue Without Additional Patient Requirement

News

A Phase 3 clinical trial evaluating AB Science’s masitinib as a treatment for progressive multiple sclerosis can continue without having to add patients, an independent review board ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Anti-inflammatory Therapies May Be More Beneficial for Younger SPMS Patients, Study Suggests

News

Older patients with secondary progressive multiple sclerosis (SPMS) have reduced risk of experiencing disease relapse, according to a study presented at the 7th Joint ECTRIMS-ACTRIMS Meeting, being ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – Tysabri Did Improve Walking and Hand Function in Failed SPMS Trial, Researchers Say

News

While Tysabri (natalizumab) failed to slow worsening disability in people with secondary progressive multiple sclerosis (SPMS) in a Phase 3 trial, researchers now suggest that the ... Read more

October 26, 2017October 27, 2017

#MSParis2017 – Siponimod Leads to Dramatic Drop in MS Lesions, Phase 3 Trial Shows

News

Novartis’ Siponimod led to a dramatic drop in the number of inflammation patches in the brains and spinal cords of secondary progressive multiple sclerosis patients, according to a ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – Lemtrada and Tysabri More Efficient Than Older Injectables in Preventing SPMS Onset, Study Finds

News

Sanofi Genzyme‘s Lemtrada (alemtuzumab) and Biogen‘s Tysabri (natalizumab) are more effective in preventing conversion to secondary progressive multiple sclerosis (SPMS) compared to older injectable drugs, researchers ... Read more

October 26, 2017October 27, 2017

#MSParis2017 – Types of Brain and Spinal Cord Lesions Help Determine if MS Develops, Study Reports

News

This is a special edition of Multiple Sclerosis News Today’s daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway ... Read more

October 18, 2017

Journalist With MS Explains the Importance of Stretching

Trevis Gleason is a food journalist who also writes about his journey with secondary-progressive multiple sclerosis (SPMS). Gleason was diagnosed with the disease in 2001 and ... Read more

July 28, 2017July 28, 2017

Arise Clinics Are Offering Ocrevus to Multiple Sclerosis Patients in Washington Area

News

Five clinics in the Washington area that specialize in administering intravenous and injected treatments to people with chronic diseases are now offering the new multiple sclerosis therapy ... Read more

July 25, 2017July 26, 2017

New Innate Analysis Fails to Show Clinical Benefit of MIS416 for Secondary Progressive MS Patients

News

A new analysis of Phase 2 clinical data on Innate Immunotherapeutics’ investigational drug MIS416 to treat secondary progressive multiple sclerosis has confirmed that the drug failed ... Read more

July 6, 2017July 6, 2017

Lipoic Acid, an Over-the-counter Antioxidant, Seen to Slow Brain Atrophy in SPMS Patients

News

The over-the-counter antioxidant lipoic acid slowed brain deterioration in patients with secondary progressive multiple sclerosis (SPMS), according to a pilot study. An Oregon Health & Science University ... Read more

July 5, 2017July 5, 2017

MIS416 Fails to Benefit Secondary Progressive MS Patients in Phase 2 Clinical Trial

News

Innate Immunotherapeutics’ MIS416 has failed to help secondary progressive multiple sclerosis (SPMS) patients in a Phase 2 clinical trial. The company said it will continue testing the ... Read more

June 21, 2017June 21, 2017

Fatigue and Reduced Leg Function Can Signal Transition to Progressive MS, Study Reports

News

Fatigue and limited leg function are more common among older people with progressive multiple sclerosis than in those with relapsing forms of the disease, according to a ... Read more

June 14, 2017June 14, 2017

SPMS Patients Have Higher Illness Burden than RRMS Patients, Kantar Health Study Shows

News

Patients with secondary progressive multiple sclerosis (SPMS) have a higher burden of illness than patients with relapsing-remitting multiple sclerosis, a new study showed. The study, “Characteristics, ... Read more

June 8, 2017June 8, 2017

High-dose Simvastatin Improves Cognitive Function in MS, New Analysis of Trial Results Reports

News

A high daily dose of simvastatin improves multiple sclerosis patients’ cognitive function, according to a new analysis of Phase 2 clinical trial results. The British team that ... Read more

May 26, 2017May 26, 2017

#CMSC17 – Tysabri Improves Mental Outlook for Patients with Secondary Progressive Multiple Sclerosis

News

Long-term therapy with Tysabri (natalizumab) significantly improved the mental state of people with secondary progressive multiple sclerosis (SPMS), according to results of a Biogen-supported study with patients ... Read more

May 11, 2017May 15, 2017

NMSS, British Partners to Launch Phase 3 Trial to Determine Efficacy of Simvastatin in SPMS Patients

News

The National Multiple Sclerosis Society (NMSS), together with its British partners, plans to launch a Phase 3 trial in the next few months to investigate whether simvastatin — ... Read more

April 28, 2017April 28, 2017

Siponimod Slows Progression of MS Disability, Phase 3 Clinical Trial Shows

News

Siponimod slows the progression of multiple sclerosis patients’ disability, a Phase 3 clinical trial indicates. The therapy reduced the risk of disability progression in patients with secondary ... Read more

April 24, 2017April 24, 2017

ATA188, Which Kills B-Cells Targeting Epstein-Barr Virus, Shows Promise as MS Treatment

News

An investigational treatment called ATA188 that wipes out B-cells targeting the Epstein-Barr virus (EBV) has shown promise as a multiple sclerosis treatment, a Phase 1 clinical trial ... Read more

March 7, 2017March 7, 2017

Older SPMS Patients More Likely to Suffer from Fatigue, Limited Leg Function, Study Says

News

People with secondary progressive multiple sclerosis (SPMS) are more likely to feel exhausted and have limited leg function than those without progressive MS as they age, a preliminary ... Read more

March 6, 2017March 6, 2017

Innate to Complete Phase 2b Trial for MIS416 Therapy in Secondary Progressive MS Patients

News

Australia’s Innate Immunotherapeutics confirmed that its Phase 2b clinical trial evaluating the drug MIS416 in patients with secondary progressive multiple sclerosis (SPMS) will wrap up by April ... Read more

February 21, 2017February 21, 2017

Stem Cell Transplants of Greatest Benefit to RMS Patients at Earlier Disease Stages, Study Says

News

Stem cell transplants are most effective if done in young multiple sclerosis (MS) patients in early disease stages, who have not gone through several rounds of other treatments, ... Read more

February 15, 2017February 15, 2017

Gilenya Could Help Treat SPMS by Countering Astrocytes, Study Says

News

Gilenya (fingolimod) a multiple sclerosis (MS) drug developed to target the immune system and control inflammation, can also reduce the negative action of astrocytes, further controlling inflammation, ... Read more

January 6, 2017January 6, 2017

Cyclophosphamide May Delay Disability in Secondary Progressive MS, but Tolerability Is an Issue, Study Shows

News

Cyclophosphamide (CPM) may delay the progression of disability in the first years of secondary progressive multiple sclerosis (SPMS), but patients must take it for two years — ... Read more

September 21, 2016September 21, 2016

#ECTRIMS2016 – Novartis’s Siponimod Appears to Slow SPMS Progression in Phase 3 Study

News

A presentation at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress gave patients with progressive multiple sclerosis (MS) a reason for optimism, ... Read more

September 19, 2016September 19, 2016

#ECTRIMS2016 – Antioxidant Lipoic Acid Appears to Slow SPMS Patients’ Neurodegeneration

News

A pilot study exploring the antioxidant lipoic acid in patients with secondary progressive multiple sclerosis (SPMS) demonstrated that treatment for two years reduced the speed of ... Read more

September 19, 2016September 19, 2016

#ECTRIMS2016 – Brain MRI Scans Can Predict Which Patients Will Progress into SPMS

News

The presence of certain brain and spinal cord lesions can be used to predict if an MS patient with clinically isolated syndrome will progress into relapsing ... Read more

September 16, 2016September 16, 2016

#ECTRIMS2016 – Inflammatory Profiles of Brain Seen to Predict MS Disability

News

Immune activity in brain membranes may be the key to determining inflammatory profiles in the brain. These profiles, in turn, are linked to levels of brain ... Read more

August 29, 2016October 31, 2016

Gilenya-like Therapy Shows Benefit in Secondary Progressive MS Patients in Phase 3 Trial

News

Patients with secondary progressive multiple sclerosis (SPMS) who were treated with BAF312 (siponimod), a sphingosine-1-phosphate (S1P) inhibitor, in a Phase 3 clinical trial showed a  significantly reduced risk for disability ... Read more

August 3, 2016August 3, 2016

Phase 2 Study of Oral Antibiotic to Treat Relapsing MS, RHB-104, Nearing Finish

News

RedHill Biopharma announced that the final patient has completed the last step of its Phase 2 clinical study (CEASE-MS) of RHB-104 as a potential treatment for people with relapsing-remitting ... Read more

June 16, 2016June 16, 2016

New Zealand Clinical Trial to Test Potential of Antipsychotics to Treat SPMS

News

An immunologist at Victoria University of Wellington is leading a clinical trial that will use existing drugs in a new way to try to treat secondary progressive multiple sclerosis (SPMS), ... Read more

April 15, 2016April 15, 2016

Innate Immunotherapeutics Fully Enrolls Phase 2 Study of Drug Candidate to Treat SPMS

News

Innate Immunotherapeutics, Ltd., announced that it has completed patient enrollment in its ongoing Phase 2B, placebo-controlled clinical trial assessing the efficacy and safety of the drug MIS416 as a once-weekly treatment for secondary progressive ... Read more

April 8, 2016

4 Types of Multiple Sclerosis

The clinical manifestation of symptoms (CMS) that lead to multiple sclerosis starts with the first symptomatic ‘attack’ indicative of the first signs of neurological damage (demyelination), ... Read more

April 5, 2016April 5, 2016

New Clinical Trial Data on Experimental MS Therapeutic Vaccine, Xemys, Released

News

PJSC Pharmsynthez, a pharmaceutical company based in Russia, recently announced completed follow-up findings and data analysis from a Phase 2a proof-of-concept clinical trial of its novel therapeutic ... Read more

March 23, 2016May 14, 2016

Potential Progressive MS Treatment, Ibudilast, Approved for Fast Track Development by FDA

News

MediciNova, Inc., announced that MN-166 (ibudilast) has been approved for “fast track” development by the U.S. Food and Drug Administration (FDA) as a potential treatment for progressive multiple sclerosis (MS). Progressive MS ... Read more

February 19, 2016February 19, 2016

ACTRIMS 2016 Talk Weighs Clinical Differences, Similarities in 2 Major Forms of MS

News

Dr. Wayne Moore, from the University of British Columbia and the Vancouver General Hospital, will present an overview and analysis of the major histology and pathology ... Read more

February 19, 2016February 19, 2016

Results of New SPMS Study to Be Presented at ACTRIMS

News

At the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, being held from Feb. 18–20 in New Orleans, LA, researchers have gathered to discuss ... Read more

February 18, 2016February 19, 2016

NIH Study into Progressive MS Biomarkers to Be Presented at ACTRIMS 2016

News

Scientists from the Neuroimmunological Diseases Unit at the National Institutes of Health (NIH) will present results of a study investigating several biomarkers that might lead to a more sensitive ... Read more

January 19, 2016

Anti-LINGO-1: All You Need to Know

Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what is Anti-LINGO-1? ... Read more

December 14, 2015December 14, 2015

2016 Multiple Sclerosis Forum to Focus on Distinctions in Disease Forms

News

Dr. Jerry S. Wolinsky of the University of Texas in Houston, will give the first Kenneth P. Johnson Memorial Lecture at the opening day of the Americas Committee for ... Read more

December 4, 2015December 4, 2015

Some RRMS and SPMS Patients Share a Similar Gene Expression in Response to IFN Treatment

News

In a new study entitled “Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis,” a team of researchers discovered a subgroup of ... Read more